Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis

Relationship to Histological Improvement

Glen Lutchman, Kittichai Promrat, David E. Kleiner, Theo Heller, Marc G. Ghany, Jack A. Yanovski, T. Jake Liang, Jay H. Hoofnagle

Research output: Contribution to journalArticle

Abstract

Background & Aims: Thiazolidinedione (TZD) therapy improves liver histology in nonalcoholic steatohepatitis (NASH) through a mechanism possibly related to its insulin-sensitizing or anti-inflammatory activity. This study was conducted to assess changes in serum levels of selected adipokines and proinflammatory cytokines and to relate these changes to the improved liver histology resulting from pioglitazone therapy for NASH. Methods: Serum samples from 18 patients with NASH obtained at day 0 and week 48 of therapy during an open-label study of pioglitazone were tested for adiponectin, leptin, interleukin (IL)-1a, IL-6, and tumor necrosis factor (TNF)-α levels. Paired liver biopsy specimens were scored (0-4) for steatosis, parenchymal inflammation, cell injury, and fibrosis. Results: Adiponectin levels increased from 3.7 to 10.3 μg/mL at week 48 (P <.01); the levels of the other cytokines were unchanged: TNF-α, 9.1 vs 8.8 pg/mL; IL-1a, 3.9 vs 3.4 pg/mL; IL-6, 19.4 vs 13.4 pg/mL; and leptin, 24.8 vs 29.6 ng/mL (P > .05 for all). Pioglitazone therapy was associated with improvements in steatosis (2.5 vs 1.0), parenchymal inflammation (3.3 vs 2.1), cell injury (2.2 vs 0.9), and fibrosis (2.0 vs 1.4). The change in adiponectin level was associated with the improvement in steatosis (P = .03) as well as in a summary NASH activity index score (P = .01). Changes in IL-1, IL-6, TNF-α, and leptin levels did not correlate with improvements in the histological features. Conclusions: Improvements in liver histology during TZD therapy may be modulated by an adiponectin-mediated effect on insulin sensitivity and hepatic fatty acid metabolism rather than by changes in proinflammatory cytokines.

Original languageEnglish (US)
Pages (from-to)1048-1052
Number of pages5
JournalClinical Gastroenterology and Hepatology
Volume4
Issue number8
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

pioglitazone
Adipokines
Adiponectin
Liver
Serum
Histology
Leptin
Interleukin-6
Fibrosis
Tumor Necrosis Factor-alpha
Cytokines
Inflammation
Therapeutics
Interleukins
Wounds and Injuries
Interleukin-1
Insulin Resistance
Anti-Inflammatory Agents
Fatty Acids
Non-alcoholic Fatty Liver Disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis : Relationship to Histological Improvement. / Lutchman, Glen; Promrat, Kittichai; Kleiner, David E.; Heller, Theo; Ghany, Marc G.; Yanovski, Jack A.; Liang, T. Jake; Hoofnagle, Jay H.

In: Clinical Gastroenterology and Hepatology, Vol. 4, No. 8, 08.2006, p. 1048-1052.

Research output: Contribution to journalArticle

Lutchman, Glen ; Promrat, Kittichai ; Kleiner, David E. ; Heller, Theo ; Ghany, Marc G. ; Yanovski, Jack A. ; Liang, T. Jake ; Hoofnagle, Jay H. / Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis : Relationship to Histological Improvement. In: Clinical Gastroenterology and Hepatology. 2006 ; Vol. 4, No. 8. pp. 1048-1052.
@article{2177c132321545c9a9aeb3d0037d1cb5,
title = "Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement",
abstract = "Background & Aims: Thiazolidinedione (TZD) therapy improves liver histology in nonalcoholic steatohepatitis (NASH) through a mechanism possibly related to its insulin-sensitizing or anti-inflammatory activity. This study was conducted to assess changes in serum levels of selected adipokines and proinflammatory cytokines and to relate these changes to the improved liver histology resulting from pioglitazone therapy for NASH. Methods: Serum samples from 18 patients with NASH obtained at day 0 and week 48 of therapy during an open-label study of pioglitazone were tested for adiponectin, leptin, interleukin (IL)-1a, IL-6, and tumor necrosis factor (TNF)-α levels. Paired liver biopsy specimens were scored (0-4) for steatosis, parenchymal inflammation, cell injury, and fibrosis. Results: Adiponectin levels increased from 3.7 to 10.3 μg/mL at week 48 (P <.01); the levels of the other cytokines were unchanged: TNF-α, 9.1 vs 8.8 pg/mL; IL-1a, 3.9 vs 3.4 pg/mL; IL-6, 19.4 vs 13.4 pg/mL; and leptin, 24.8 vs 29.6 ng/mL (P > .05 for all). Pioglitazone therapy was associated with improvements in steatosis (2.5 vs 1.0), parenchymal inflammation (3.3 vs 2.1), cell injury (2.2 vs 0.9), and fibrosis (2.0 vs 1.4). The change in adiponectin level was associated with the improvement in steatosis (P = .03) as well as in a summary NASH activity index score (P = .01). Changes in IL-1, IL-6, TNF-α, and leptin levels did not correlate with improvements in the histological features. Conclusions: Improvements in liver histology during TZD therapy may be modulated by an adiponectin-mediated effect on insulin sensitivity and hepatic fatty acid metabolism rather than by changes in proinflammatory cytokines.",
author = "Glen Lutchman and Kittichai Promrat and Kleiner, {David E.} and Theo Heller and Ghany, {Marc G.} and Yanovski, {Jack A.} and Liang, {T. Jake} and Hoofnagle, {Jay H.}",
year = "2006",
month = "8",
doi = "10.1016/j.cgh.2006.05.005",
language = "English (US)",
volume = "4",
pages = "1048--1052",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis

T2 - Relationship to Histological Improvement

AU - Lutchman, Glen

AU - Promrat, Kittichai

AU - Kleiner, David E.

AU - Heller, Theo

AU - Ghany, Marc G.

AU - Yanovski, Jack A.

AU - Liang, T. Jake

AU - Hoofnagle, Jay H.

PY - 2006/8

Y1 - 2006/8

N2 - Background & Aims: Thiazolidinedione (TZD) therapy improves liver histology in nonalcoholic steatohepatitis (NASH) through a mechanism possibly related to its insulin-sensitizing or anti-inflammatory activity. This study was conducted to assess changes in serum levels of selected adipokines and proinflammatory cytokines and to relate these changes to the improved liver histology resulting from pioglitazone therapy for NASH. Methods: Serum samples from 18 patients with NASH obtained at day 0 and week 48 of therapy during an open-label study of pioglitazone were tested for adiponectin, leptin, interleukin (IL)-1a, IL-6, and tumor necrosis factor (TNF)-α levels. Paired liver biopsy specimens were scored (0-4) for steatosis, parenchymal inflammation, cell injury, and fibrosis. Results: Adiponectin levels increased from 3.7 to 10.3 μg/mL at week 48 (P <.01); the levels of the other cytokines were unchanged: TNF-α, 9.1 vs 8.8 pg/mL; IL-1a, 3.9 vs 3.4 pg/mL; IL-6, 19.4 vs 13.4 pg/mL; and leptin, 24.8 vs 29.6 ng/mL (P > .05 for all). Pioglitazone therapy was associated with improvements in steatosis (2.5 vs 1.0), parenchymal inflammation (3.3 vs 2.1), cell injury (2.2 vs 0.9), and fibrosis (2.0 vs 1.4). The change in adiponectin level was associated with the improvement in steatosis (P = .03) as well as in a summary NASH activity index score (P = .01). Changes in IL-1, IL-6, TNF-α, and leptin levels did not correlate with improvements in the histological features. Conclusions: Improvements in liver histology during TZD therapy may be modulated by an adiponectin-mediated effect on insulin sensitivity and hepatic fatty acid metabolism rather than by changes in proinflammatory cytokines.

AB - Background & Aims: Thiazolidinedione (TZD) therapy improves liver histology in nonalcoholic steatohepatitis (NASH) through a mechanism possibly related to its insulin-sensitizing or anti-inflammatory activity. This study was conducted to assess changes in serum levels of selected adipokines and proinflammatory cytokines and to relate these changes to the improved liver histology resulting from pioglitazone therapy for NASH. Methods: Serum samples from 18 patients with NASH obtained at day 0 and week 48 of therapy during an open-label study of pioglitazone were tested for adiponectin, leptin, interleukin (IL)-1a, IL-6, and tumor necrosis factor (TNF)-α levels. Paired liver biopsy specimens were scored (0-4) for steatosis, parenchymal inflammation, cell injury, and fibrosis. Results: Adiponectin levels increased from 3.7 to 10.3 μg/mL at week 48 (P <.01); the levels of the other cytokines were unchanged: TNF-α, 9.1 vs 8.8 pg/mL; IL-1a, 3.9 vs 3.4 pg/mL; IL-6, 19.4 vs 13.4 pg/mL; and leptin, 24.8 vs 29.6 ng/mL (P > .05 for all). Pioglitazone therapy was associated with improvements in steatosis (2.5 vs 1.0), parenchymal inflammation (3.3 vs 2.1), cell injury (2.2 vs 0.9), and fibrosis (2.0 vs 1.4). The change in adiponectin level was associated with the improvement in steatosis (P = .03) as well as in a summary NASH activity index score (P = .01). Changes in IL-1, IL-6, TNF-α, and leptin levels did not correlate with improvements in the histological features. Conclusions: Improvements in liver histology during TZD therapy may be modulated by an adiponectin-mediated effect on insulin sensitivity and hepatic fatty acid metabolism rather than by changes in proinflammatory cytokines.

UR - http://www.scopus.com/inward/record.url?scp=33746340885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746340885&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2006.05.005

DO - 10.1016/j.cgh.2006.05.005

M3 - Article

VL - 4

SP - 1048

EP - 1052

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 8

ER -